Evidence map›Paper›PMID 29924108›Full record

ReviewThe Analyst2018

Optical assays based on colloidal inorganic nanoparticles.

Amir Ghasemi, Navid Rabiee, Sepideh Ahmadi, Shabnam Hashemzadeh, Farshad Lolasi, Mahnaz Bozorgomid, Alireza Kalbasi, Behzad Nasseri, Amin Shiralizadeh Dezfuli, Amir Reza Aref and 2 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Analyst, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 77 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Review
  13. Review
  14. Article
  15. Green chemistry and coronavirus.Sustainable chemistry and pharmacy · 2021
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 5 countries.

Amir GhasemiDepartment of Materials Science and Engineering, Sharif University of Technology, Tehran, Iran and Advances Nanobiotechnology and Nanomedicine Research Group (ANNRG), Iran University of Medical Sciences, Tehran, Iran.
Navid RabieeDepartment of Chemistry, Shahid Beheshti University, Tehran, Iran.ORCID http://orcid.org/0000-0002-6945-8541
Sepideh AhmadiAdvances Nanobiotechnology and Nanomedicine Research Group (ANNRG), Iran University of Medical Sciences, Tehran, Iran and Department of Biology, Faculty of Basic Sciences, University of Zabol, Zabol, Iran.
Shabnam HashemzadehDepartment of Medical Physics and Biomedical Engineering, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran and Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Science, Tabriz, Iran.
Farshad LolasiDepartment of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Isfahan, Isfahan, 81746-73441, Iran and Department of Agronomy and Plant Breeding, College of Agriculture, Isfahan University of Technology, Isfahan, Iran.ORCID http://orcid.org/0000-0003-4419-5543
Mahnaz BozorgomidDepartment of Pharmaceutical Chemistry, Islamic Azad University of Pharmaceutical Sciences Branch, Tehran, Iran.
Alireza KalbasiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Behzad NasseriDepartments of Microbiology and Microbial Biotechnology and Nanobiotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran and Chemical Engineering Deptartment and Bioengineeing Division, Hacettepe University, 06800, Beytepe, Ankara, Turkey.
Amin Shiralizadeh DezfuliAdvances Nanobiotechnology and Nanomedicine Research Group (ANNRG), Iran University of Medical Sciences, Tehran, Iran and Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-8628-3010
Amir Reza ArefBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Mahdi KarimiCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran. m_karimy2006@yahoo.com karimi.m@iums.ac.ir and Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran and Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Hamblin@helix.mgh.harvard.edu.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Hamblin@helix.mgh.harvard.edu and Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA and Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA.ORCID http://orcid.org/0000-0001-6431-4605
Harvard University · USDana-Farber Cancer Institute · USEcologie Microbienne Lyon · FRFaculty (United Kingdom) · GBIran University of Medical Sciences · IRIsfahan University of Technology · IRIslamic Azad University Pharmaceutical Sciences Branch · IRShahid Beheshti University · IRSharif University of Technology · IRZabol University · IR

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract InfectionsR21AI121700 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2016 to 2017
$462k
NIAID NIH HHS R01 AI050875NIAID NIH HHS R21 AI121700
6 · The paper itself

Abstract

Colloidal inorganic nanoparticles have wide applications in the detection of analytes and in biological assays. A large number of these assays rely on the ability of gold nanoparticles (AuNPs, in the 20 nm diameter size range) to undergo a color change from red to blue upon aggregation. AuNP assays can be based on cross-linking, non-cross linking or unmodified charge-based aggregation. Nucleic acid-based probes, monoclonal antibodies, and molecular-affinity agents can be attached by covalent or non-covalent means. Surface plasmon resonance and SERS techniques can be utilized. Silver NPs also have attractive optical properties (higher extinction coefficient). Combinations of AuNPs and AgNPs in nanocomposites can have additional advantages. Magnetic NPs and ZnO, TiO

Indexed as

ColorimetryMetal NanoparticlesGoldNanocompositesSilicon DioxideSilverGoldSilicon DioxideSilver

Identifiers

PMID29924108
PMCPMC6042520
OpenAlexW2808482379

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.